{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T06:46:09Z","timestamp":1758091569963,"version":"3.44.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":6477,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","fertstert.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Fertility and Sterility"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1016\/j.fertnstert.2004.07.935","type":"journal-article","created":{"date-parts":[[2005,2,16]],"date-time":"2005-02-16T11:23:33Z","timestamp":1108553013000},"page":"26-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"S1","title":["Hormonal contraception: Recent advances and controversies"],"prefix":"10.1016","volume":"82","member":"78","reference":[{"key":"10.1016\/j.fertnstert.2004.07.935_BIB1","unstructured":"Speroff L, Glass RH, Kase NG, eds. Clinical gynecologic endocrinology and infertility. Baltimore: 1999;867\u2013945"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0010-7824(95)00014-2","article-title":"A multicentered phase III comparative clinical trial of Mesigyna, Cyclofem and Injectable No. 1 given by intramuscular injection to Chinese women. II. The comparison of bleeding patterns","volume":"51","author":"Sang","year":"1995","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0010-7824(99)00083-9","volume":"60","author":"Kaunitz","year":"1999","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB4","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0010-7824(00)00183-9","volume":"62","author":"Garceau","year":"2000","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0010-7824(99)00081-5","article-title":"Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension)","volume":"60","author":"Rahimy","year":"1999","journal-title":"Contraception"},{"issue":"Suppl 2","key":"10.1016\/j.fertnstert.2004.07.935_BIB6","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0015-0282(01)03261-7","article-title":"Pharmacokinetic overview of Ortho Evra\/Evra","volume":"77","author":"Abrams","year":"2002","journal-title":"Fertil Steril"},{"issue":"Suppl 2","key":"10.1016\/j.fertnstert.2004.07.935_BIB7","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0015-0282(01)03275-7","article-title":"Contraceptive efficacy and cycle control with the Ortho Evra\/Evra transdermal system","volume":"77","author":"Zieman","year":"2002","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB8","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1001\/jama.285.18.2347","article-title":"Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive","volume":"285","author":"Audet","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB9","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0015-0282(01)01689-2","article-title":"Use of novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition","volume":"75","author":"Mulders","year":"2001","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/humrep\/16.3.469","article-title":"Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl estradiol","volume":"16","author":"Roumen","year":"2001","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB11","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1055\/s-2001-18643","article-title":"Progestin-releasing intrauterine systems","volume":"19","author":"Luukkainen","year":"2001","journal-title":"Semin Reprod Med"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/0010-7824(94)90109-0","article-title":"Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use","volume":"49","author":"Andersson","year":"1994","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB13","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0010-7824(77)90001-4","article-title":"Comparative quantitation of menstrual blood loss with a d-norgestrel-releasing IUD and a Nova-T-copper device","volume":"15","author":"Nilsson","year":"1977","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0010-7824(01)00302-X","article-title":"Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years","volume":"65","author":"Hidalgo","year":"2002","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB15","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0002-9378(11)90607-3","article-title":"Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices","volume":"166","author":"Sivin","year":"1992","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB16","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1093\/humrep\/13.12.3371","article-title":"The performance of levonorgestrel rod and Norplant contraceptive implants","volume":"13","author":"Sivin","year":"1998","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB17","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0010-7824(98)00112-7","article-title":"Contraception with two levonorgestrel rod implants. A 5-year study in the United States and Dominican Republic","volume":"58","author":"Sivin","year":"1998","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB18","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1055\/s-2001-18642","article-title":"Implant contraception","volume":"19","author":"Meckstroth","year":"2001","journal-title":"Semin Reprod Med"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB19","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1067\/mob.2001.117415","article-title":"Preclinical profiles of progestins used in formulations of oral contraceptives and hormone replacement therapy","volume":"185","author":"Hammond","year":"2001","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0010-7824(00)00133-5","article-title":"Drospirenone","volume":"62","author":"Krattenmacher","year":"2000","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB21","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0015-0282(00)01747-7","article-title":"The emerging use of the 20-microg oral contraceptive","volume":"75","author":"Poindexter","year":"2001","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB22","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0010-7824(99)00109-2","article-title":"Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives","volume":"60","author":"Rosenberg","year":"1999","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB23","first-page":"771","article-title":"Menstrual reduction with extended use of combination oral contraceptive pills","volume":"98","author":"Miller","year":"2001","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0010-7824(02)00445-6","article-title":"Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive","volume":"67","author":"Kwiecien","year":"2003","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB25","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(98)05718-3","article-title":"Timing of emergency contraception with levonorgestrel or the Yuzpe regimen. Task Force on Postovulatory Methods of Fertility Regulation","volume":"353","author":"Piaggio","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB26","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0010-7824(98)00042-0","article-title":"New estimates of the effectiveness of the Yuzpe regimen of emergency contraception","volume":"57","author":"Trussell","year":"1998","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0010-7824(99)00018-9","article-title":"Updated estimates of the effectiveness of the Yuzpe regimen of emergency contraception","volume":"59","author":"Trussell","year":"1999","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB28","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(98)05145-9","article-title":"Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB29","first-page":"271","article-title":"Meclizine for prevention of nausea associated with use of emergency contraceptive pills","volume":"95","author":"Raymond","year":"2000","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB30","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0010-7824(00)00178-5","article-title":"Ectopic gestation following emergency contraceptive pill administration","volume":"62","author":"Nielsen","year":"2000","journal-title":"Contraception"},{"year":"2001","series-title":"ACOG practice bulletin no. 25: emergency oral contraception","key":"10.1016\/j.fertnstert.2004.07.935_BIB31"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB32","doi-asserted-by":"crossref","unstructured":"Comparison of three single doses of mifepristone as emergency contraception: a randomised trial. Task Force on Postovulatory Methods of Fertility Regulation. Lancet 1999;353:697\u2013702","DOI":"10.1016\/S0140-6736(98)07190-6"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB33","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1471-0528.2002.01371.x","article-title":"A randomised study comparing a low dose of mifepristone and the Yuzpe regimen for emergency contraception","volume":"109","author":"Ashok","year":"2002","journal-title":"BJOG"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB34","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1056\/NEJM199210083271501","article-title":"Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception","volume":"327","author":"Glasier","year":"1992","journal-title":"N Engl J Med"},{"year":"2003","series-title":"SEER cancer statistics review, 1975-2000","author":"Ries","key":"10.1016\/j.fertnstert.2004.07.935_BIB35"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB36","doi-asserted-by":"crossref","unstructured":"Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713\u201327","DOI":"10.1016\/S0140-6736(96)90806-5"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB37","series-title":"Estrogens and progestogens in clinical practice","first-page":"831","article-title":"The influence of steroids on gynecologic cancers","author":"Schlesselman","year":"1999"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB38","doi-asserted-by":"crossref","unstructured":"The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. Combination oral contraceptive use and the risk of endometrial cancer. JAMA 1987;257:796\u2013800","DOI":"10.1001\/jama.1987.03390060086029"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB39","first-page":"277","article-title":"Use of oral contraceptives and endometrial cancer risk (Sweden)","volume":"10","author":"Weiderpass","year":"1999","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB40","doi-asserted-by":"crossref","unstructured":"The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. Int J Cancer 1991;49:186\u201390","DOI":"10.1002\/ijc.2910490207"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB41","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/0029-7844(95)00022-J","article-title":"Net effect of oral contraceptive use on the risk of cancer in women in the United States","volume":"85","author":"Schlesselman","year":"1995","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB42","doi-asserted-by":"crossref","unstructured":"The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. The reduction in risk of ovarian cancer associated with oral contraceptive use. N Engl J Med 1987;316:650\u20135","DOI":"10.1056\/NEJM198703123161102"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB43","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/jnci\/94.1.32","article-title":"Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk","volume":"94","author":"Schildkraut","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB44","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJM199808133390702","article-title":"Oral contraceptives and the risk of hereditary ovarian cancer. Hereditory Ovarian Cancer Clinical Study Group","volume":"339","author":"Narod","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB45","first-page":"419","article-title":"The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer","volume":"83","author":"Gross","year":"1994","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB46","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/(SICI)1097-0215(19990505)81:3<357::AID-IJC8>3.0.CO;2-1","article-title":"Smoking and oral contraceptives as risk factors for cervical carcinoma in situ","volume":"81","author":"Ylitalo","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB47","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1054\/bjoc.1999.1100","article-title":"Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection","volume":"82","author":"Kjellberg","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB48","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/gye.15.1.23.28","article-title":"The evidence for an etiological relationship between oral contraceptive use and dysplastic change in cervical tissue","volume":"15","author":"Salazar","year":"2001","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB49","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(02)08150-3","article-title":"Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection","volume":"359","author":"Moreno","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB50","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J Pathol"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB51","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S0140-6736(02)08125-4","article-title":"Oral contraceptives, parity, and cervical cancer","volume":"359","author":"Skegg","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB52","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(02)08151-5","article-title":"Role of parity and human papillomavirus in cervical cancer","volume":"359","author":"Munoz","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB53","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1054\/bjoc.2000.1622","article-title":"Oral contraceptives and colorectal cancer risk","volume":"84","author":"Fernandez","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB54","first-page":"569","article-title":"Spinal bone density in women using depot medroxyprogesterone contraception","volume":"92","author":"Cundy","year":"1998","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB55","first-page":"736","article-title":"Steroid hormone contraception and bone mineral density","volume":"95","author":"Petitti","year":"2000","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB56","first-page":"576","article-title":"A prospective, controlled study of the effects of hormonal contraception on bone mineral density","volume":"98","author":"Berenson","year":"2001","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB57","unstructured":"American College of Obstetricians and Gynecologists. ACOG committee revises recommendations on OCs with third-generation progestins. ACOG Today 1998;July"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB58","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/bmj.308.6923.247","article-title":"Recovery of bone density in women who stop using medroxyprogesterone acetate","volume":"308","author":"Cundy","year":"1994","journal-title":"BMJ"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB59","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1046\/j.1365-2265.1998.00582.x","article-title":"The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women","volume":"49","author":"Orr-Walker","year":"1998","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB60","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0022-3476(96)70148-8","article-title":"A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives","volume":"129","author":"Cromer","year":"1996","journal-title":"J Pediatr"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB61","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0010-7824(95)00121-P","article-title":"Differential effects on bone density of progestogen-only methods for contraception in premenopausal women","volume":"52","author":"Naessen","year":"1995","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB62","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2265.1993.tb02422.x","article-title":"Effects of norethisterone on bone related biochemical variables and forearm bone mineral in post-menopausal osteoporosis","volume":"39","author":"Horowitz","year":"1993","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB63","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1001\/archinte.1991.00400100053009","article-title":"Oral contraceptive use may protect against low bone mass. Henry Ford Hospital Osteoporosis Cooperative Research Group","volume":"151","author":"Kleerekoper","year":"1991","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB64","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(98)09044-8","article-title":"Oral-contraceptive use and risk of hip fracture","volume":"353","author":"Michaelsson","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB65","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0015-0282(01)01936-7","article-title":"Forearm bone density in long-term users of oral combined contraceptives and depot medroxyprogesterone acetate","volume":"76","author":"Perrotti","year":"2001","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB66","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/humupd\/5.6.721","article-title":"Cardiovascular disease and combined oral contraceptives","volume":"5","author":"Farley","year":"1999","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB67","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa003216","article-title":"Oral contraceptives and the risk of myocardial infarction","volume":"345","author":"Tanis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB68","doi-asserted-by":"crossref","unstructured":"WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. Lancet 1997;349:1202\u20139","DOI":"10.1016\/S0140-6736(97)02358-1"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB69","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1161\/01.STR.0000015345.61324.3F","article-title":"Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study","volume":"33","author":"Kemmeren","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB70","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/bmj.318.7175.13","article-title":"Migraine and stroke in young women","volume":"318","author":"Chang","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB71","first-page":"1100","article-title":"Contraception for women in selected circumstances","volume":"99","author":"Curtis","year":"2002","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB72","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/oxfordjournals.aje.a115799","article-title":"Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease","volume":"133","author":"Gerstman","year":"1991","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB73","doi-asserted-by":"crossref","unstructured":"World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995;346:1582\u20138","DOI":"10.1016\/S0140-6736(95)91927-9"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB74","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/bmj.323.7305.131","article-title":"Third generation oral contraceptives and risk of venous thrombosis","volume":"323","author":"Kemmeren","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB75","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1055\/s-2001-18638","article-title":"The risks of oral contraceptive pills","volume":"19","author":"Pymar","year":"2001","journal-title":"Semin Reprod Med"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB76","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(94)90286-0","article-title":"Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation","volume":"344","author":"Vandenbroucke","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB77","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJM200105173442007","article-title":"Oral contraceptives and the risk of venous thrombosis","volume":"344","author":"Vandenbroucke","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2004.07.935_BIB78","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1161\/01.ATV.19.3.700","article-title":"Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis","volume":"19","author":"Martinelli","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["Fertility and Sterility"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001502820402357X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001502820402357X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T07:01:01Z","timestamp":1758006061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001502820402357X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":78,"alternative-id":["S001502820402357X"],"URL":"https:\/\/doi.org\/10.1016\/j.fertnstert.2004.07.935","relation":{},"ISSN":["0015-0282"],"issn-type":[{"type":"print","value":"0015-0282"}],"subject":[],"published":{"date-parts":[[2004,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hormonal contraception: Recent advances and controversies","name":"articletitle","label":"Article Title"},{"value":"Fertility and Sterility","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fertnstert.2004.07.935","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}